Cargando…
Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment
Ribociclib is a newly approved orally administered drug for breast cancer. This study aimed to prepare, characterize, and evaluate hybrid lipid–polymer nanoparticles (PLNs) of ribociclib to enhance its in vitro dissolution rate, pharmacokinetics, and anticancer efficacy. Ribociclib-loaded PLNs were...
Autores principales: | Al-Shdefat, Ramadan, Hailat, Mohammad, Alshogran, Osama Y., Abu Dayyih, Wael, Gardouh, Ahmed, Al Meanazel, Osaid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347058/ https://www.ncbi.nlm.nih.gov/pubmed/37447489 http://dx.doi.org/10.3390/polym15132844 |
Ejemplares similares
-
Pharmacokinetics and Bioequivalence of Two Empagliflozin, with Evaluation in Healthy Jordanian Subjects under Fasting and Fed Conditions
por: Hailat, Mohammad, et al.
Publicado: (2022) -
Esomeprazole and apixaban pharmacokinetic interactions in healthy rats
por: Jaber, Ali, et al.
Publicado: (2022) -
Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma
por: Hailat, Mohammad, et al.
Publicado: (2021) -
Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition
por: Alanazi, Saleh A., et al.
Publicado: (2021) -
Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome
por: Anwer, Md. K., et al.
Publicado: (2017)